Results 11 to 20 of about 2,826,854 (328)

Structural Basis for Inhibitor-Induced Aggregation of HIV Integrase. [PDF]

PLoS Biology, 2016
The allosteric inhibitors of integrase (termed ALLINIs) interfere with HIV replication by binding to the viral-encoded integrase (IN) protein. Surprisingly, ALLINIs interfere not with DNA integration but with viral particle assembly late during HIV ...
Kushol Gupta, Vesa Turkki, Scott Sherrill-Mix, Young Hwang, Grant Eilers, Louis Taylor, Charlene McDanal, Ping Wang, David Temelkoff, Robert T Nolte, Emile Velthuisen, Jerry Jeffrey, Gregory D Van Duyne, Frederic D Bushman   +13 more
doaj   +2 more sources

Weight and Metabolic Outcomes in Naïve HIV Patients Treated with Integrase Inhibitor-Based Antiretroviral Therapy: A Systematic Review and Meta-Analysis. [PDF]

J Clin Med, 2023
Background: The use of integrase inhibitor-based antiretroviral therapy could be associated with worse weight and metabolic outcomes in patients with HIV infection. Methods: PubMed, EMBASE, and Scopus were searched from inception to March 2022.
Valenzuela-Rodriguez G, Diaz-Arocutipa C, Collins JA, Hernandez AV.   +3 more
europepmc   +2 more sources

Raltegravir: first in class HIV integrase inhibitor

Therapeutics and Clinical Risk Management, 2008
Zelalem Temesgen1, Dawd S Siraj21Mayo Clinic, Rochester, MN, USA; 2East Carolina University Greenville, NC, USAAbstract: On October 16, 2007, the US Food and Drug Administration (FDA) approved raltegravir for treatment of human immunodeficiency virus ...
Zelalem Temesgen, Dawd S Siraj
doaj   +5 more sources

Weight change with antiretroviral switch from integrase inhibitor or tenofovir alafenamide-based to Doravirine-Based regimens in people with HIV [PDF]

HIV Research & Clinical Practice
Background Weight gain has been well-described with integrase strand transfer inhibitors (INSTIs) and tenofovir alafenamide (TAF). Doravirine (DOR) has been identified as a relatively “weight-neutral” drug; however, there is little data describing its ...
Arianna E. Kousari, Melissa P. Wilson, Kellie L. Hawkins, Mohamed Mehdi Bandali, Andrés F. Henao-Martínez, Edward M. Gardner, Kristine M. Erlandson   +6 more
doaj   +2 more sources

Efavirenz Pharmacogenetics and Weight Gain Following Switch to Integrase Inhibitor-Containing Regimens. [PDF]

Clin Infect Dis, 2021
BACKGROUND Unwanted weight gain affects some people living with HIV who are prescribed integrase strand transfer inhibitors (INSTI). Mechanisms and risk factors are incompletely understood.
Leonard MA, Cindi Z, Bradford Y, Bourgi K, Koethe J, Turner M, Norwood J, Woodward B, Erdem H, Basham R, Baker P, Rebeiro PF, Sterling TR, Hulgan T, Daar ES, Gulick R, Riddler SA, Sinxadi P, Ritchie MD, Haas DW.   +19 more
europepmc   +2 more sources

Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study. [PDF]

Antimicrob Agents Chemother, 2022
At week 48 in the phase IIIb DAWNING study, the integrase strand transfer inhibitor (INSTI) dolutegravir plus 2 nucleoside reverse transcriptase inhibitors demonstrated superiority to ritonavir-boosted lopinavir in achieving virologic suppression in ...
Underwood M, Horton J, Nangle K, Hopking J, Smith K, Aboud M, Wynne B, Sievers J, Stewart EL, Wang R.   +9 more
europepmc   +2 more sources

Predictors of Virological Failure and Time to Viral Suppression of First-Line Integrase Inhibitor-Based Antiretroviral Treatment. [PDF]

Clin Infect Dis, 2021
Background Integrase strand transfer inhibitors (InSTIs) are recommended for first-line treatment of persons with human immunodeficiency virus (HIV). We identified risk factors, including baseline minor InSTI resistance mutations, for treatment failure ...
Pyngottu A, Scherrer AU, Kouyos R, Huber M, Hirsch H, Perreau M, Yerly S, Calmy A, Cavassini M, Stöckle M, Furrer H, Vernazza P, Bernasconi E, Günthard HF, Swiss HIV Cohort Study.   +14 more
europepmc   +2 more sources

Risk Factors for Weight Gain Following Switch to Integrase Inhibitor-Based Antiretroviral Therapy. [PDF]

Clin Infect Dis, 2020
BACKGROUND Treatment initiation with integrase strand transfer inhibitors (INSTIs) has been associated with excess weight gain. Whether similar gains are seen after switch to INSTI among virologically suppressed persons is less clear.
Lake JE, Wu K, Bares SH, Debroy P, Godfrey C, Koethe JR, McComsey GA, Palella FJ, Tassiopoulos K, Erlandson KM.   +9 more
europepmc   +2 more sources

Weight gain and integrase inhibitors [PDF]

Current Opinion in Infectious Diseases, 2020
Purpose of review Weight gain and obesity among people living with HIV (PLWH) is a serious problem that occurs often after initiation of antiretroviral therapy but may be worse with integrase strand transfer inhibitors (INSTIs).
Grace A. McComsey, Allison Ross Eckard
openaire   +3 more sources

Assessment of Obesity and Cardiometabolic Status by Integrase Inhibitor Use in REPRIEVE: A Propensity-Weighted Analysis of a Multinational Primary Cardiovascular Prevention Cohort of People With Human Immunodeficiency Virus

Open Forum Infectious Diseases, 2021
Background Emerging data demonstrate that the use of integrase inhibitor (INSTI)-based antiretroviral treatment (ART) is associated with increased weight, but the cardiometabolic health consequences of increased weight remains poorly understood.
E. M. Kileel, J. Lo, C. Malvestutto, Kathleen V. Fitch, M. Zanni, C. Fichtenbaum, E. Overton, N. Okeke, Princy N. Kumar, E. Joao, J. Aberg, E. Martínez, J. Currier, P. Douglas, H. Ribaudo, S. Grinspoon   +15 more
semanticscholar   +1 more source